An observational study in Human Papillomavirus Infection, sponsored by GlaxoSmithKline. Completed at 2 sites in Egypt. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-16.
Sponsored by GlaxoSmithKline · Observational
The purpose of the study is to determine the Human Papillomavirus (HPV) prevalence and HPV type distribution among women aged >= 18 years, attending out-patient health services for gynaecological examination and who agree to HPV testing in Egypt .
495 studies on the registry are indexed under Papillomavirus Infections; 125 are open to participants now.
This study's enrollment of 490 is above the median of 400 across 147 observational studies indexed under Papillomavirus Infections.
Browse Papillomavirus Infections studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Women >= 18 attending out-patient departments of primary, secondary or tertiary care centres for gynaecological examination and agreeing to provide a cervical sample for human papillomavirus testing.
Exclusion Criteria:
Subjects attending out-patient health services for gynaecological examination.
Procedure: Endocervical samples
Endocervical samples collection during routine gynaecological examinations.
Occurrence of Human papillomavirus (HPV) DNA and of any of the HPV types among women undergoing cervical sample testing.
Time frame: Average timeframe: 12 months
Occurrence of HPV DNA and of any of the HPV types among women of different age-strata undergoing cervical sample testing
Time frame: Average timeframe: 12 months
Behavioural risk factors assessed by behavioral questionnaire
Time frame: At the single study visit (Day 0)
Assessing the awareness of HPV in relation to transmission and cause of cervical cancer
Time frame: At the single study visit (Day 0)
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline